 Azathioprine
"Azathioprine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An immunosuppressive agent used in combination with cyclophosphamide and hydroxychloroquine in the treatment of rheumatoid arthritis. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), this substance has been listed as a known carcinogen. (Merck Index, 11th ed)
| Descriptor ID |
D001379
|
| MeSH Number(s) |
D02.886.759.111 D03.438.759.534.090 D13.570.900.111
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Azathioprine".
Below are MeSH descriptors whose meaning is more specific than "Azathioprine".
This graph shows the total number of publications written about "Azathioprine" by people in this website by year, and whether "Azathioprine" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1980 | 0 | 1 | 1 | | 1982 | 1 | 0 | 1 | | 1983 | 0 | 1 | 1 | | 1984 | 0 | 1 | 1 | | 1985 | 1 | 0 | 1 | | 1986 | 0 | 1 | 1 | | 1987 | 0 | 2 | 2 | | 1989 | 1 | 1 | 2 | | 1992 | 0 | 2 | 2 | | 1993 | 1 | 5 | 6 | | 1994 | 0 | 1 | 1 | | 1995 | 2 | 2 | 4 | | 1996 | 0 | 3 | 3 | | 1997 | 0 | 6 | 6 | | 1998 | 1 | 3 | 4 | | 1999 | 1 | 3 | 4 | | 2000 | 0 | 2 | 2 | | 2001 | 0 | 3 | 3 | | 2002 | 1 | 0 | 1 | | 2004 | 2 | 2 | 4 | | 2005 | 2 | 1 | 3 | | 2006 | 1 | 3 | 4 | | 2007 | 1 | 1 | 2 | | 2008 | 1 | 1 | 2 | | 2009 | 1 | 2 | 3 | | 2010 | 1 | 3 | 4 | | 2011 | 1 | 0 | 1 | | 2013 | 6 | 1 | 7 | | 2014 | 0 | 1 | 1 | | 2015 | 0 | 1 | 1 | | 2016 | 1 | 1 | 2 | | 2018 | 3 | 1 | 4 | | 2020 | 1 | 1 | 2 | | 2021 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Azathioprine" by people in Profiles.
-
Reder AT, Centonze D, Naylor ML, Nagpal A, Rajbhandari R, Altincatal A, Kim M, Berdofe A, Radhakrishnan M, Jung E, Sandrock AW, Smirnakis K, Popescu C, de Moor C. COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies. CNS Drugs. 2021 03; 35(3):317-330.
-
Mahadevan U, Long MD, Kane SV, Roy A, Dubinsky MC, Sands BE, Cohen RD, Chambers CD, Sandborn WJ. Pregnancy and Neonatal Outcomes After Fetal Exposure to Biologics and Thiopurines Among Women With Inflammatory Bowel Disease. Gastroenterology. 2021 03; 160(4):1131-1139.
-
Anandi P, Dickson AL, Feng Q, Wei WQ, Dupont WD, Plummer D, Liu G, Octaria R, Barker KA, Kawai VK, Birdwell K, Cox NJ, Hung A, Stein CM, Chung CP. Combining clinical and candidate gene data into a risk score for azathioprine-associated leukopenia in routine clinical practice. Pharmacogenomics J. 2020 10; 20(5):736-745.
-
Colombel JF, Adedokun OJ, Gasink C, Gao LL, Cornillie FJ, D'Haens GR, Rutgeerts PJ, Reinisch W, Sandborn WJ, Hanauer SB. Combination Therapy With Infliximab and Azathioprine Improves Infliximab Pharmacokinetic Features and Efficacy: A Post Hoc Analysis. Clin Gastroenterol Hepatol. 2019 07; 17(8):1525-1532.e1.
-
Hanauer SB, Sandborn WJ, Lichtenstein GR. Evolving Considerations for Thiopurine Therapy for Inflammatory Bowel Diseases-A Clinical Practice Update: Commentary. Gastroenterology. 2019 01; 156(1):36-42.
-
Yarur AJ, Gondal B, Hirsch A, Christensen B, Cohen RD, Rubin DT. Higher Thioguanine Nucleotide Metabolite Levels are Associated With Better Long-term Outcomes in Patients With Inflammatory Bowel Diseases. J Clin Gastroenterol. 2018 07; 52(6):537-544.
-
Friedman AB, Brown SJ, Bampton P, Barclay ML, Chung A, Macrae FA, McKenzie J, Reynolds J, Gibson PR, Hanauer SB, Sparrow MP. Randomised clinical trial: efficacy, safety and dosage of adjunctive allopurinol in azathioprine/mercaptopurine nonresponders (AAA Study). Aliment Pharmacol Ther. 2018 Apr; 47(8):1092-1102.
-
Oldham JM, Lee C, Valenzi E, Witt LJ, Adegunsoye A, Hsu S, Chen L, Montner S, Chung JH, Noth I, Vij R, Strek ME. Azathioprine response in patients with fibrotic connective tissue disease-associated interstitial lung disease. Respir Med. 2016 12; 121:117-122.
-
Cabral DA, Canter DL, Muscal E, Nanda K, Wahezi DM, Spalding SJ, Twilt M, Benseler SM, Campillo S, Charuvanij S, Dancey P, Eberhard BA, Elder ME, Hersh A, Higgins GC, Huber AM, Khubchandani R, Kim S, Klein-Gitelman M, Kostik MM, Lawson EF, Lee T, Lubieniecka JM, McCurdy D, Moorthy LN, Morishita KA, Nielsen SM, O'Neil KM, Reiff A, Ristic G, Robinson AB, Sarmiento A, Shenoi S, Toth MB, Van Mater HA, Wagner-Weiner L, Weiss JE, White AJ, Yeung RS. Comparing Presenting Clinical Features in 48 Children With Microscopic Polyangiitis to 183 Children Who Have Granulomatosis With Polyangiitis (Wegener's): An ARChiVe Cohort Study. Arthritis Rheumatol. 2016 10; 68(10):2514-26.
-
Bellaguarda E, Keyashian K, Pekow J, Rubin DT, Cohen RD, Sakuraba A. Prevalence of Antibodies Against JC Virus in Patients With Refractory Crohn's Disease and Effects of Natalizumab Therapy. Clin Gastroenterol Hepatol. 2015 Nov; 13(11):1919-25.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|